CU-CPT8m | TLR8 antagonist

CU-CPT8m chemical structure

Available Options

Size:PriceQuantity 
5 mg$70.00
25 mg$230.00
Request Quote / Bulk / Custom Size
Product Inquiry

CU-CPT8m (125079-83-6) is a potent and selective antagonist of toll-like receptor 8 (TLR8) acting via stabilization of the TLR8 homodimer.1 It inhibits TNFα and IL-8 expression induced by the TLR8 agonist resiquimod at 1 mM and suppresses TLR8-mediated proinflammatory signaling in various cell lines, human primary cells and patient specimens. It reverses phenotypes involved in TLR8-activating fibroblasts.2 CU-CPT8m promotes erythroid cell proliferation and differentiation.3

References/Citations:

  1. Zhang et al. (2018), Small-molecule inhibition of TLR8 through stabilization of its resting state; Nat. Chem. Biol. 14 58
  2. Kong et al. (2024), TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis; Rheumatology (Oxford) 63 1710
  3. Liang et al. (2024), Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia; Nat. Commun. 15 5678
125079-83-6, CU-CPT8m, CU-CPT8m supplier, CUCPT8m, TLR8 antagonist

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

CU-CPT8m (125079-83-6) is a potent and selective antagonist of toll-like receptor 8 (TLR8) acting via stabilization of the TLR8 homodimer.1 It inhibits TNFα and IL-8 expression induced by the TLR8 agonist resiquimod at 1 mM and suppresses TLR8-mediated proinflammatory signaling in various cell lines, human primary cells and patient specimens. It reverses phenotypes involved in TLR8-activating fibroblasts.2 CU-CPT8m promotes erythroid cell proliferation and differentiation.3

References/Citations:

  1. Zhang et al. (2018), Small-molecule inhibition of TLR8 through stabilization of its resting state; Nat. Chem. Biol. 14 58
  2. Kong et al. (2024), TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis; Rheumatology (Oxford) 63 1710
  3. Liang et al. (2024), Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia; Nat. Commun. 15 5678